- Home
- PMM vs CERS Comparison
PMM vs CERS Comparison
Compare PMM & CERS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- PMM
- CERS
- Stock Information
- Founded
- PMM 1989
- CERS 1991
- Country
- PMM United States
- CERS United States
- Employees
- PMM N/A
- CERS N/A
- Industry
- PMM Investment Managers
- CERS EDP Services
- Sector
- PMM Finance
- CERS Technology
- Exchange
- PMM Nasdaq
- CERS Nasdaq
- Market Cap
- PMM 251.7M
- CERS 255.0M
- IPO Year
- PMM N/A
- CERS 1997
- Fundamental
- Price
- PMM $6.17
- CERS $1.26
- Analyst Decision
- PMM
- CERS Strong Buy
- Analyst Count
- PMM 0
- CERS 2
- Target Price
- PMM N/A
- CERS $3.50
- AVG Volume (30 Days)
- PMM 118.3K
- CERS 1.1M
- Earning Date
- PMM 01-01-0001
- CERS 10-29-2025
- Dividend Yield
- PMM 4.68%
- CERS N/A
- EPS Growth
- PMM N/A
- CERS N/A
- EPS
- PMM 0.23
- CERS N/A
- Revenue
- PMM N/A
- CERS $192,510,000.00
- Revenue This Year
- PMM N/A
- CERS $30.03
- Revenue Next Year
- PMM N/A
- CERS $9.37
- P/E Ratio
- PMM $26.52
- CERS N/A
- Revenue Growth
- PMM N/A
- CERS 13.25
- 52 Week Low
- PMM $5.00
- CERS $1.12
- 52 Week High
- PMM $6.42
- CERS $2.24
- Technical
- Relative Strength Index (RSI)
- PMM 52.77
- CERS 48.39
- Support Level
- PMM N/A
- CERS $1.20
- Resistance Level
- PMM $6.10
- CERS $1.27
- Average True Range (ATR)
- PMM 0.05
- CERS 0.06
- MACD
- PMM -0.19
- CERS -0.00
- Stochastic Oscillator
- PMM 99.84
- CERS 50.00
About PMM Putnam Managed Municipal Income Trust
Putnam Managed Municipal Income Trust is a closed-end management investment company. Its investment objective is to seek a high level of current income exempt from federal income tax by investing in a diversified portfolio of tax-exempt municipal securities. The Fund invests in various sectors such as healthcare, retirement community, private higher education, housing-backed, essential service utilities, and state-backed bonds.
About CERS Cerus Corporation
Cerus Corp is a biomedical products company focused on the field of blood transfusion safety. The INTERCEPT Blood System is designed to reduce the risk of transfusion-transmitted infections by inactivating a broad range of pathogens such as viruses, bacteria, and parasites. The company sells its INTERCEPT platelet and plasma systems in the United States of America, Europe, the Commonwealth of Independent States countries, the Middle East, and selected countries in other regions around the world. The firm continues to operate in only one segment: Blood safety and generates revenue from the same.